Tuning acetylation levels with HAT activators: Therapeutic strategy in neurodegenerative diseases

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1799, Issue 10-12, 2010, Pages 840-853

  Selvi, B Ruthrotha ^a   Cassel, Jean Christophe ^b   Kundu, Tapas K ^a   Boutillier, Anne Laurence ^c  

^a JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH   (India)

^b Centre de Neurochimie   (France)

^c UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Acetylation; CREB binding protein; Histone acetyltransferase; Memory; Neurodegenerative disease; Neuronal death

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; BINDING PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP; HISTIDINE; HISTONE ACETYLTRANSFERASE; HISTONE ACETYLTRANSFERASE GCN5; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H4; NEUROPROTECTIVE AGENT; NONHISTONE PROTEIN; POLYGLUTAMINE; PROTEIN ARGININE METHYLTRANSFERASE; PROTEIN P300; REGULATOR PROTEIN; SAGA ANTIGEN; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CHROMATIN; DEGENERATIVE DISEASE; GENE EXPRESSION; HUMAN; HUNTINGTON CHOREA; MEMORY; NERVE CELL PLASTICITY; NONHUMAN; PARKINSON DISEASE; PHOSPHORYLATION; PRIORITY JOURNAL; REVIEW; SURFACE PLASMON RESONANCE;

EID: 78649891582     PISSN: 18749399     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2010.08.012     Document Type: Review

References (197)

1. Fadeel B., Orrenius S. Apoptosis: a basic biological phenomenon with wide-ranging implications in human disease. J. Intern. Med. 2005, 258:479-517.
2. Chouliaras L., Rutten B.P., Kenis G., Peerbooms O., Visser P.J., Verhey F., van Os J., Steinbusch H.W., van den Hove D.L. Epigenetic regulation in the pathophysiology of Alzheimer's disease. Prog. Neurobiol. 2010, 90:498-510.
3. Graff J., Mansuy I.M. Epigenetic dysregulation in cognitive disorders. Eur. J. Neurosci. 2009, 30:1-8.
4. Bird A. Perceptions of epigenetics. Nature 2007, 447:396-398.
5. Kouzarides T. Chromatin modifications and their function. Cell 2007, 128:693-705.
6. Hargreaves D.C., Horng T., Medzhitov R. Control of inducible gene expression by signal-dependent transcriptional elongation. Cell 2009, 138:129-145.
7. Vogelauer M., Wu J., Suka N., Grunstein M. Global histone acetylation and deacetylation in yeast. Nature 2000, 408:495-498.
8. Nagy Z., Tora L. Distinct GCN5/PCAF-containing complexes function as co-activators and are involved in transcription factor and global histone acetylation. Oncogene 2007, 26:5341-5357.
9. Berger S.L. The complex language of chromatin regulation during transcription. Nature 2007, 447:407-412.
10. Rando O.J., Chang H.Y. Genome-wide views of chromatin structure. Annu. Rev. Biochem. 2009, 78:245-271.
11. Wang Z., Zang C., Cui K., Schones D.E., Barski A., Peng W., Zhao K. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell 2009, 138:1019-1031.
12. Kazantsev A.G., Thompson L.M. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat. Rev. Drug Discov. 2008, 7:854-868.
13. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 2006, 5:769-784.
14. Zhang Y., Li N., Caron C., Matthias G., Hess D., Khochbin S., Matthias P. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J. 2003, 22:1168-1179.
15. Gu W., Shi X.L., Roeder R.G. Synergistic activation of transcription by CBP and p53. Nature 1997, 387:819-823.
16. Lill N.L., Grossman S.R., Ginsberg D., DeCaprio J., Livingston D.M. Binding and modulation of p53 by p300/CBP coactivators. Nature 1997, 387:823-827.
17. Chao C., Saito S., Kang J., Anderson C.W., Appella E., Xu Y. p53 transcriptional activity is essential for p53-dependent apoptosis following DNA damage. EMBO J. 2000, 19:4967-4975.
18. Luo J., Su F., Chen D., Shiloh A., Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 2000, 408:377-381.
19. Appella E., Anderson C.W. Signaling to p53: breaking the posttranslational modification code. Pathol. Biol. (Paris) 2000, 48:227-245.
20. Rouaux C., Loeffler J.P., Boutillier A.L. Targeting CREB-binding protein (CBP) loss of function as a therapeutic strategy in neurological disorders. Biochem. Pharmacol. 2004, 68:1157-1164.
21. Saha R.N., Pahan K. HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis. Cell Death Differ. 2006, 13:539-550.
22. Sleiman S.F., Basso M., Mahishi L., Kozikowski A.P., Donohoe M.E., Langley B., Ratan R.R. Putting the 'HAT' back on survival signalling: the promises and challenges of HDAC inhibition in the treatment of neurological conditions. Expert Opin. Investig. Drugs 2009, 18:573-584.
23. Barrett R.M., Wood M.A. Beyond transcription factors: the role of chromatin modifying enzymes in regulating transcription required for memory. Learn. Mem. 2008, 15:460-467.
24. Roth T.L., Sweatt J.D. Regulation of chromatin structure in memory formation. Curr. Opin. Neurobiol. 2009, 19:336-342.
25. de Ruijter A.J., van Gennip A.H., Caron H.N., Kemp S., van Kuilenburg A.B. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 2003, 370:737-749.
26. Haberland M., Montgomery R.L., Olson E.N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet. 2009, 10:32-42.
27. Lee K.K., Workman J.L. Histone acetyltransferase complexes: one size doesn't fit all. Nat. Rev. Mol. Cell Biol. 2007, 8:284-295.
28. Roth S.Y., Denu J.M., Allis C.D. Histone acetyltransferases. Annu. Rev. Biochem. 2001, 70:81-120.
29. Qin S., Parthun M.R. Histone H3 and the histone acetyltransferase Hat1p contribute to DNA double-strand break repair. Mol. Cell. Biol. 2002, 22:8353-8365.
30. Neuwald A.F., Landsman D. GCN5-related histone N-acetyltransferases belong to a diverse superfamily that includes the yeast SPT10 protein. Trends Biochem. Sci. 1997, 22:154-515.
31. Tanner K.G., Trievel R.C., Kuo M.H., Howard R.M., Berger S.L., Allis C.D., Marmorstein R., Denu J.M. Catalytic mechanism and function of invariant glutamic acid 173 from the histone acetyltransferase GCN5 transcriptional coactivator. J. Biol. Chem. 1999, 274:18157-18160.
32. Trievel R.C., Rojas J.R., Sterner D.E., Venkataramani R.N., Wang L., Zhou J., Allis C.D., Berger S.L., Marmorstein R. Crystal structure and mechanism of histone acetylation of the yeast GCN5 transcriptional coactivator. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:8931-8936.
33. Bu P., Evrard Y.A., Lozano G., Dent S.Y. Loss of Gcn5 acetyltransferase activity leads to neural tube closure defects and exencephaly in mouse embryos. Mol. Cell. Biol. 2007, 27:3405-3416.
34. Ogryzko V.V., Kotani T., Zhang X., Schiltz R.L., Howard T., Yang X.J., Howard B.H., Qin J., Nakatani Y. Histone-like TAFs within the PCAF histone acetylase complex. Cell 1998, 94:35-44.
35. Yamauchi T., Yamauchi J., Kuwata T., Tamura T., Yamashita T., Bae N., Westphal H., Ozato K., Nakatani Y. Distinct but overlapping roles of histone acetylase PCAF and of the closely related PCAF-B/GCN5 in mouse embryogenesis. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:11303-11306.
36. Wang Y.L., Faiola F., Xu M., Pan S., Martinez E. Human ATAC Is a GCN5/PCAF-containing acetylase complex with a novel NC2-like histone fold module that interacts with the TATA-binding protein. J. Biol. Chem. 2008, 283:33808-33815.
37. Suganuma T., Gutierrez J.L., Li B., Florens L., Swanson S.K., Washburn M.P., Abmayr S.M., Workman J.L. ATAC is a double histone acetyltransferase complex that stimulates nucleosome sliding. Nat. Struct. Mol. Biol. 2008, 15:364-372.
38. Winkler G.S., Kristjuhan A., Erdjument-Bromage H., Tempst P., Svejstrup J.Q. Elongator is a histone H3 and H4 acetyltransferase important for normal histone acetylation levels in vivo. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:3517-3522.
39. Wittschieben B.O., Otero G., de Bizemont T., Fellows J., Erdjument-Bromage H., Ohba R., Li Y., Allis C.D., Tempst P., Svejstrup J.Q. A novel histone acetyltransferase is an integral subunit of elongating RNA polymerase II holoenzyme. Mol. Cell 1999, 4:123-128.
40. Slaugenhaupt S.A., Blumenfeld A., Gill S.P., Leyne M., Mull J., Cuajungco M.P., Liebert C.B., Chadwick B., Idelson M., Reznik L., Robbins C., Makalowska I., Brownstein M., Krappmann D., Scheidereit C., Maayan C., Axelrod F.B., Gusella J.F. Tissue-specific expression of a splicing mutation in the IKBKAP gene causes familial dysautonomia. Am. J. Hum. Genet. 2001, 68:598-605.
41. Creppe C., Malinouskaya L., Volvert M.L., Gillard M., Close P., Malaise O., Laguesse S., Cornez I., Rahmouni S., Ormenese S., Belachew S., Malgrange B., Chapelle J.P., Siebenlist U., Moonen G., Chariot A., Nguyen L. Elongator controls the migration and differentiation of cortical neurons through acetylation of alpha-tubulin. Cell 2009, 136:551-564.
42. Reed N.A., Cai D., Blasius T.L., Jih G.T., Meyhofer E., Gaertig J., Verhey K.J. Microtubule acetylation promotes kinesin-1 binding and transport. Curr. Biol. 2006, 16:2166-2172.
43. Hubbert C., Guardiola A., Shao R., Kawaguchi Y., Ito A., Nixon A., Yoshida M., Wang X.F., Yao T.P. HDAC6 is a microtubule-associated deacetylase. Nature 2002, 417:455-458.
44. Matsuyama A., Shimazu T., Sumida Y., Saito A., Yoshimatsu Y., Seigneurin-Berny D., Osada H., Komatsu Y., Nishino N., Khochbin S., Horinouchi S., Yoshida M. In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J. 2002, 21:6820-6831.
45. Dompierre J.P., Godin J.D., Charrin B.C., Cordelieres F.P., King S.J., Humbert S., Saudou F. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. J. Neurosci. 2007, 27:3571-3583.
46. Simpson C.L., Lemmens R., Miskiewicz K., Broom W.J., Hansen V.K., van Vught P.W., Landers J.E., Sapp P., Van Den Bosch L., Knight J., Neale B.M., Turner M.R., Veldink J.H., Ophoff R.A., Tripathi V.B., Beleza A., Shah M.N., Proitsi P., Van Hoecke A., Carmeliet P., Horvitz H.R., Leigh P.N., Shaw C.E., van den Berg L.H., Sham P.C., Powell J.F., Verstreken P., Brown R.H., Robberecht W., Al-Chalabi A. Variants of the elongator protein 3 (ELP3) gene are associated with motor neuron degeneration. Hum. Mol. Genet. 2009, 18:472-481.
47. Nguyen L., Humbert S., Saudou F., Chariot A. Elongator - an emerging role in neurological disorders. Trends Mol. Med. 2010, 16:1-6.
48. Bordoli L., Husser S., Luthi U., Netsch M., Osmani H., Eckner R. Functional analysis of the p300 acetyltransferase domain: the PHD finger of p300 but not of CBP is dispensable for enzymatic activity. Nucleic Acids Res. 2001, 29:4462-4471.
49. Kalkhoven E., Teunissen H., Houweling A., Verrijzer C.P., Zantema A. The PHD type zinc finger is an integral part of the CBP acetyltransferase domain. Mol. Cell. Biol. 2002, 22:1961-1970.
50. Marmorstein R., Trievel R.C. Histone modifying enzymes: structures, mechanisms, and specificities. Biochim. Biophys. Acta. 2009, 1789:58-68.
51. Liu X., Wang L., Zhao K., Thompson P.R., Hwang Y., Marmorstein R., Cole P.A. The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. Nature 2008, 451:846-850.
52. Thompson P.R., Wang D., Wang L., Fulco M., Pediconi N., Zhang D., An W., Ge Q., Roeder R.G., Wong J., Levrero M., Sartorelli V., Cotter R.J., Cole P.A. Regulation of the p300 HAT domain via a novel activation loop. Nat. Struct. Mol. Biol. 2004, 11:308-315.
53. Grossman S.R., Deato M.E., Brignone C., Chan H.M., Kung A.L., Tagami H., Nakatani Y., Livingston D.M. Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science 2003, 300:342-344.
54. Shi D., Pop M.S., Kulikov R., Love I.M., Kung A.L., Grossman S.R. CBP and p300 are cytoplasmic E4 polyubiquitin ligases for p53. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:16275-16280.
55. Bhattacherjee V., Horn K.H., Singh S., Webb C.L., Pisano M.M., Greene R.M. CBP/p300 and associated transcriptional co-activators exhibit distinct expression patterns during murine craniofacial and neural tube development. Int. J. Dev. Biol. 2009, 53:1097-1104.
56. Oike Y., Hata A., Mamiya T., Kaname T., Noda Y., Suzuki M., Yasue H., Nabeshima T., Araki K., Yamamura K. Truncated CBP protein leads to classical Rubinstein-Taybi syndrome phenotypes in mice: implications for a dominant-negative mechanism. Hum. Mol. Genet. 1999, 8:387-396.
57. Yao T.P., Oh S.P., Fuchs M., Zhou N.D., Ch'ng L.E., Newsome D., Bronson R.T., Li E., Livingston D.M., Eckner R. Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 1998, 93:361-372.
58. Chrivia J.C., Kwok R.P., Lamb N., Hagiwara M., Montminy M.R., Goodman R.H. Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature 1993, 365:855-985.
59. Tang Y., Holbert M.A., Wurtele H., Meeth K., Rocha W., Gharib M., Jiang E., Thibault P., Verreault A., Cole P.A., Marmorstein R. Fungal Rtt109 histone acetyltransferase is an unexpected structural homolog of metazoan p300/CBP. Nat. Struct. Mol. Biol. 2008, 15:998.
60. Dekker F.J., Haisma H.J. Histone acetyl transferases as emerging drug targets. Drug Discov. Today 2009, 14:942-948.
61. Heery D.M., Fischer P.M. Pharmacological targeting of lysine acetyltransferases in human disease: a progress report. Drug Discov. Today 2007, 12:88-99.
62. Yang X.J. The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic Acids Res. 2004, 32:959-976.
63. Ait-Si-Ali S., Polesskaya A., Filleur S., Ferreira R., Duquet A., Robin P., Vervish A., Trouche D., Cabon F., Harel-Bellan A. CBP/p300 histone acetyl-transferase activity is important for the G1/S transition. Oncogene 2000, 19:2430-2437.
64. Iyer N.G., Xian J., Chin S.F., Bannister A.J., Daigo Y., Aparicio S., Kouzarides T., Caldas C. p300 is required for orderly G1/S transition in human cancer cells. Oncogene 2007, 26:21-29.
65. Katsumoto T., Yoshida N., Kitabayashi I. Roles of the histone acetyltransferase monocytic leukemia zinc finger protein in normal and malignant hematopoiesis. Cancer Sci. 2008, 99:1523-1527.
66. Kitabayashi I., Aikawa Y., Yokoyama A., Hosoda F., Nagai M., Kakazu N., Abe T., Ohki M. Fusion of MOZ and p300 histone acetyltransferases in acute monocytic leukemia with a t(8;22)(p11;q13) chromosome translocation. Leukemia 2001, 15:89-94.
67. Thomas T., Voss A.K. The diverse biological roles of MYST histone acetyltransferase family proteins. Cell Cycle 2007, 6:696-704.
68. Yan Y., Harper S., Speicher D.W., Marmorstein R. The catalytic mechanism of the ESA1 histone acetyltransferase involves a self-acetylated intermediate. Nat. Struct. Biol. 2002, 9:862-869.
69. Berndsen C.E., Albaugh B.N., Tan S., Denu J.M. Catalytic mechanism of a MYST family histone acetyltransferase. Biochemistry 2007, 46:623-629.
70. Voss A.K., Thomas T. MYST family histone acetyltransferases take center stage in stem cells and development. Bioessays 2009, 31:1050-1061.
71. Avvakumov N., Cote J. The MYST family of histone acetyltransferases and their intimate links to cancer. Oncogene 2007, 26:5395-5407.
72. Squatrito M., Gorrini C., Amati B. Tip60 in DNA damage response and growth control: many tricks in one HAT. Trends Cell Biol. 2006, 16:433-442.
73. Hu Y., Fisher J.B., Koprowski S., McAllister D., Kim M.S., Lough J. Homozygous disruption of the Tip60 gene causes early embryonic lethality. Dev. Dyn. 2009, 238:2912-2921.
74. Andrisani O.M. CREB-mediated transcriptional control. Crit. Rev. Eukaryot. Gene Expr. 1999, 9:19-32.
75. Sen N., Hara M.R., Kornberg M.D., Cascio M.B., Bae B.I., Shahani N., Thomas B., Dawson T.M., Dawson V.L., Snyder S.H., Sawa A. Nitric oxide-induced nuclear GAPDH activates p300/CBP and mediates apoptosis. Nat. Cell Biol. 2008, 10:866-873.
76. Creaven M., Hans F., Mutskov V., Col E., Caron C., Dimitrov S., Khochbin S. Control of the histone-acetyltransferase activity of Tip60 by the HIV-1 transactivator protein, Tat. Biochemistry 1999, 38:8826-8830.
77. Santos-Rosa H., Valls E., Kouzarides T., Martinez-Balbas M. Mechanisms of P/CAF auto-acetylation. Nucleic Acids Res. 2003, 31:4285-4292.
78. Blanco-Garcia N., Asensio-Juan E., de la Cruz X., Martinez-Balbas M.A. Autoacetylation regulates P/CAF nuclear localization. J. Biol. Chem. 2009, 284:1343-1352.
79. Arif M., Kumar G.V., Narayana C., Kundu T.K. Autoacetylation induced specific structural changes in histone acetyltransferase domain of p300: probed by surface enhanced Raman spectroscopy. J. Phys. Chem. B 2007, 111:11877-11879.
80. Black J.C., Mosley A., Kitada T., Washburn M., Carey M. The SIRT2 deacetylase regulates autoacetylation of p300. Mol Cell 2008, 32:449-455.
81. Gregoire S., Xiao L., Nie J., Zhang X., Xu M., Li J., Wong J., Seto E., Yang X.J. Histone deacetylase 3 interacts with and deacetylates myocyte enhancer factor 2. Mol. Cell. Biol. 2007, 27:1280-1295.
82. Wang J., Chen J. SIRT1 regulates autoacetylation and histone acetyltransferase activity of TIP60. J. Biol. Chem. 2010, 285:11458-11464.
83. Chawla S., Hardingham G.E., Quinn D.R., Bading H. CBP: a signal-regulated transcriptional coactivator controlled by nuclear calcium and CaM kinase IV. Science 1998, 281:1505-1509.
84. Hardingham G.E., Chawla S., Cruzalegui F.H., Bading H. Control of recruitment and transcription-activating function of CBP determines gene regulation by NMDA receptors and L-type calcium channels. Neuron 1999, 22:789-798.
85. Chevillard-Briet M., Trouche D., Vandel L. Control of CBP co-activating activity by arginine methylation. EMBO J. 2002, 21:5457-5466.
86. Daujat S., Bauer U.M., Shah V., Turner B., Berger S., Kouzarides T. Crosstalk between CARM1 methylation and CBP acetylation on histone H3. Curr. Biol. 2002, 12:2090-2097.
87. Linares L.K., Kiernan R., Triboulet R., Chable-Bessia C., Latreille D., Cuvier O., Lacroix M., Le Cam L., Coux O., Benkirane M. Intrinsic ubiquitination activity of PCAF controls the stability of the oncoprotein Hdm2. Nat. Cell Biol. 2007, 9:331-338.
88. Balasubramanyam K., Swaminathan V., Ranganathan A., Kundu T.K. Small molecule modulators of histone acetyltransferase p300. J. Biol. Chem. 2003, 278:19134-19140.
89. Selvi B.R., Jagadeesan D., Suma B.S., Nagashankar G., Arif M., Balasubramanyam K., Eswaramoorthy M., Kundu T.K. Intrinsically fluorescent carbon nanospheres as a nuclear targeting vector: delivery of membrane-impermeable molecule to modulate gene expression in vivo. Nano Lett. 2008, 8:3182-3188.
90. Mantelingu K., Kishore A.H., Balasubramanyam K., Kumar G.V., Altaf M., Swamy S.N., Selvi R., Das C., Narayana C., Rangappa K.S., Kundu T.K. Activation of p300 histone acetyltransferase by small molecules altering enzyme structure: probed by surface-enhanced Raman spectroscopy. J. Phys. Chem. B 2007, 111:4527-4534.
91. F. Dal Piaz, A. Tosco, D. Eletto, A.L. Piccinelli, O. Moltedo, S. Franceschelli, G. Sbardella, P. Remondelli, L. Rastrelli, L. Vesci, C. Pisano, N. De Tommasi, The identification of a novel natural activator of p300 histone acetyltransferase provides new insights into the modulation mechanism of this enzyme. Chembiochem 11 (2010) 818-827.
92. Kim S.H., Kang H.J., Na H., Lee M.O. Trichostatin A enhances acetylation as well as protein stability of ER alpha through induction of p300 protein. Breast Cancer Res. 2010, 12:R22. PMID: 20388208.
93. Lee E.M., Shin S., Cha H.J., Yoon Y., Bae S., Jung J.H., Lee S.M., Lee S.J., Park I.C., Jin Y.W., An S. Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells. Int. J. Mol. Med. 2009, 24:45-50.
94. Scott G.K., Mattie M.D., Berger C.E., Benz S.C., Benz C.C. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res. 2006, 66:1277-1281.
95. Kumar P., Kalonia H., Kumar A. Huntington's disease: pathogenesis to animal models. Pharmacol. Rep. 2010, 62:1-14.
96. Yasuda T., Mochizuki H. The regulatory role of alpha-synuclein and parkin in neuronal cell apoptosis; possible implications for the pathogenesis of Parkinson's disease. Apoptosis 2010, 10. PMID: 20221696.
97. Gonzalez de Aguilar J.L., Echaniz-Laguna A., Fergani A., Rene F., Meininger V., Loeffler J.P., Dupuis L. Amyotrophic lateral sclerosis: all roads lead to Rome. J. Neurochem. 2007, 101:1153-1160.
98. Ilieva H., Polymenidou M., Cleveland D.W. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J. Cell Biol. 2009, 187:761-772.
99. Carter J., Lippa C.F. Beta-amyloid, neuronal death and Alzheimer's disease. Curr. Mol. Med. 2001, 1:733-737.
100. Terwel D., Dewachter I., Van Leuven F. Axonal transport, tau protein, and neurodegeneration in Alzheimer's disease. Neuromolecular Med. 2002, 2:151-165.
101. Rouaux C., Jokic N., Mbebi C., Boutillier S., Loeffler J.P., Boutillier A.L. Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration. EMBO J. 2003, 22:6537-6549.
102. Anne-Laurence B., Caroline R., Irina P., Jean-Philippe L. Chromatin acetylation status in the manifestation of neurodegenerative diseases: HDAC inhibitors as therapeutic tools. Subcell. Biochem. 2007, 41:263-293.
103. Steffan J.S., Bodai L., Pallos J., Poelman M., McCampbell A., Apostol B.L., Kazantsev A., Schmidt E., Zhu Y.Z., Greenwald M., Kurokawa R., Housman D.E., Jackson G.R., Marsh J.L., Thompson L.M. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001, 413:739-743.
104. Kontopoulos E., Parvin J.D., Feany M.B. Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum. Mol. Genet. 2006, 15:3012-3023.
105. Li F., Macfarlan T., Pittman R.N., Chakravarti D. Ataxin-3 is a histone-binding protein with two independent transcriptional corepressor activities. J. Biol. Chem. 2002, 277:45004-45012.
106. Rouaux C., Panteleeva I., Rene F., Gonzalez de Aguilar J.L., Echaniz-Laguna A., Dupuis L., Menger Y., Boutillier A.L., Loeffler J.P. Sodium valproate exerts neuroprotective effects in vivo through CREB-binding protein-dependent mechanisms but does not improve survival in an amyotrophic lateral sclerosis mouse model. J. Neurosci. 2007, 27:5535-5545.
107. Boutillier A.L., Trinh E., Loeffler J.P. Selective E2F-dependent gene transcription is controlled by histone deacetylase activity during neuronal apoptosis. J. Neurochem. 2003, 84:814-828.
108. Salminen A., Tapiola T., Korhonen P., Suuronen T. Neuronal apoptosis induced by histone deacetylase inhibitors. Brain Res. Mol. Brain Res. 1998, 61:203-206.
109. Song C., Kanthasamy A., Anantharam V., Sun F., Kanthasamy A.G. Environmental neurotoxic pesticide increases histone acetylation to promote apoptosis in dopaminergic neuronal cells: relevance to epigenetic mechanisms of neurodegeneration. Mol. Pharmacol. 2010, 77:621-632.
110. Graff J., Mansuy I.M. Epigenetic codes in cognition and behaviour. Behav. Brain Res. 2008, 192:70-87.
111. Fanselow M.S., Dong H.W. Are the dorsal and ventral hippocampus functionally distinct structures?. Neuron 2010, 65:7-19.
112. Frankland P.W., Bontempi B. The organization of recent and remote memories. Nat. Rev. Neurosci. 2005, 6:119-130.
113. Levenson J.M., O'Riordan K.J., Brown K.D., Trinh M.A., Molfese D.L., Sweatt J.D. Regulation of histone acetylation during memory formation in the hippocampus. J. Biol. Chem. 2004, 279:40545-40559.
114. Guan Z., Giustetto M., Lomvardas S., Kim J.H., Miniaci M.C., Schwartz J.H., Thanos D., Kandel E.R. Integration of long-term-memory-related synaptic plasticity involves bidirectional regulation of gene expression and chromatin structure. Cell 2002, 111:483-493.
115. Peleg S., Sananbenesi F., Zovoilis A., Burkhardt S., Bahari-Javan S., Agis-Balboa R.C., Cota P., Wittnam J.L., Gogol-Doering A., Opitz L., Salinas-Riester G., Dettenhofer M., Kang H., Farinelli L., Chen W., Fischer A. Altered histone acetylation is associated with age-dependent memory impairment in mice. Science 2010, 328:753-756.
116. Bredy T.W., Barad M. The histone deacetylase inhibitor valproic acid enhances acquisition, extinction, and reconsolidation of conditioned fear. Learn. Mem. 2008, 15:39-45.
117. Bredy T.W., Wu H., Crego C., Zellhoefer J., Sun Y.E., Barad M. Histone modifications around individual BDNF gene promoters in prefrontal cortex are associated with extinction of conditioned fear. Learn. Mem. 2007, 14:268-276.
118. Lattal K.M., Barrett R.M., Wood M.A. Systemic or intrahippocampal delivery of histone deacetylase inhibitors facilitates fear extinction. Behav. Neurosci. 2007, 121:1125-1131.
119. Vecsey C.G., Hawk J.D., Lattal K.M., Stein J.M., Fabian S.A., Attner M.A., Cabrera S.M., McDonough C.B., Brindle P.K., Abel T., Wood M.A. Histone deacetylase inhibitors enhance memory and synaptic plasticity via CREB:CBP-dependent transcriptional activation. J. Neurosci. 2007, 27:6128-6140.
120. Stefanko D.P., Barrett R.M., Ly A.R., Reolon G.K., Wood M.A. Modulation of long-term memory for object recognition via HDAC inhibition. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:9447-9452.
121. Bousiges O., Pereira de Vasconcelos A., Neidl R., Cosquer B., Herbeaux K., Panteleeva L., Loeffler J.P., Cassel J.C., Boutillier A.L. Spatial memory consolidation is associated with induction of several Lysine-acetyltransferase (HAT) expression levels and H2B/H4 acetylation-dependent transcriptional events in the rat hippocampus. Neuropsychopharmacology 2010, 35:2521-2537.
122. Maharana C., Sharma K.P., Sharma S.K. Depolarization induces acetylation of histone H2B in the hippocampus. Neuroscience 2010, 167:354-360.
123. Wood M.A., Hawk J.D., Abel T. Combinatorial chromatin modifications and memory storage: a code for memory?. Learn. Mem. 2006, 13:241-244.
124. Workman J.L., Kingston R.E. Alteration of nucleosome structure as a mechanism of transcriptional regulation. Annu. Rev. Biochem. 1998, 67:545-579.
125. Lehrmann H., Pritchard L.L., Harel-Bellan A. Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv. Cancer Res. 2002, 86:41-65.
126. Sauve A.A., Wolberger C., Schramm V.L., Boeke J.D. The biochemistry of sirtuins. Annu. Rev. Biochem. 2006, 75:435-465.
127. Dokmanovic M., Clarke C., Marks P.A. Histone deacetylase inhibitors: overview and perspectives. Mol. Cancer Res. 2007, 5:981-989.
128. Xu W.S., Parmigiani R.B., Marks P.A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007, 26:5541-5552.
129. Abel T., Zukin R.S. Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr. Opin. Pharmacol. 2008, 8:57-64.
130. Chuang D.M., Leng Y., Marinova Z., Kim H.J., Chiu C.T. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 2009, 32:591-601.
131. Hahnen E., Hauke J., Trankle C., Eyupoglu I.Y., Wirth B., Blumcke I. Histone deacetylase inhibitors: possible implications for neurodegenerative disorders. Expert Opin. Investig. Drugs 2008, 17:169-184.
132. Mai A., Rotili D., Valente S., Kazantsev A.G. Histone deacetylase inhibitors and neurodegenerative disorders: holding the promise. Curr. Pharm. Des. 2009, 15:3940-3957.
133. Morrison B.E., Majdzadeh N., D'Mello S.R. Histone deacetylases: focus on the nervous system. Cell. Mol. Life Sci. 2007, 64:2258-2269.
134. Gardian G., Browne S.E., Choi D.K., Klivenyi P., Gregorio J., Kubilus J.K., Ryu H., Langley B., Ratan R.R., Ferrante R.J., Beal M.F. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J. Biol. Chem. 2005, 280:556-563.
135. Hockly E., Richon V.M., Woodman B., Smith D.L., Zhou X., Rosa E., Sathasivam K., Ghazi-Noori S., Mahal A., Lowden P.A., Steffan J.S., Marsh J.L., Thompson L.M., Lewis C.M., Marks P.A., Bates G.P. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:2041-2046.
136. Minamiyama M., Katsuno M., Adachi H., Waza M., Sang C., Kobayashi Y., Tanaka F., Doyu M., Inukai A., Sobue G. Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum. Mol. Genet. 2004, 13:1183-1192.
137. Thomas E.A., Coppola G., Desplats P.A., Tang B., Soragni E., Burnett R., Gao F., Fitzgerald K.M., Borok J.F., Herman D., Geschwind D.H., Gottesfeld J.M. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:15564-15569.
138. Pallos J., Bodai L., Lukacsovich T., Purcell J.M., Steffan J.S., Thompson L.M., Marsh J.L. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum. Mol. Genet. 2008, 17:3767-3775.
139. Gardian G., Yang L., Cleren C., Calingasan N.Y., Klivenyi P., Beal M.F. Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity. Neuromolecular Med. 2004, 5:235-241.
140. Gottlicher M., Minucci S., Zhu P., Kramer O.H., Schimpf A., Giavara S., Sleeman J.P., Lo Coco F., Nervi C., Pelicci P.G., Heinzel T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001, 20:6969-6978.
141. Chen P.S., Peng G.S., Li G., Yang S., Wu X., Wang C.C., Wilson B., Lu R.B., Gean P.W., Chuang D.M., Hong J.S. Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol. Psychiatry 2006, 11:1116-1125.
142. Chen P.S., Wang C.C., Bortner C.D., Peng G.S., Wu X., Pang H., Lu R.B., Gean P.W., Chuang D.M., Hong J.S. Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience 2007, 149:203-212.
143. Outeiro T.F., Kontopoulos E., Altmann S.M., Kufareva I., Strathearn K.E., Amore A.M., Volk C.B., Maxwell M.M., Rochet J.C., McLean P.J., Young A.B., Abagyan R., Feany M.B., Hyman B.T., Kazantsev A.G. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 2007, 317:516-519.
144. Monti B., Gatta V., Piretti F., Raffaelli S.S., Virgili M., Contestabile A. Valproic acid is neuroprotective in the rotenone rat model of Parkinson's disease: involvement of alpha-synuclein. Neurotox. Res. 2010, 17:130-141.
145. Echaniz-Laguna A., Bousiges O., Loeffler J.P., Boutillier A.L. Histone deacetylase inhibitors: therapeutic agents and research tools for deciphering motor neuron diseases. Curr. Med. Chem. 2008, 15:1263-1273.
146. Petri S., Kiaei M., Kipiani K., Chen J., Calingasan N.Y., Crow J.P., Beal M.F. Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2006, 22:40-49.
147. Ryu H., Smith K., Camelo S.I., Carreras I., Lee J., Iglesias A.H., Dangond F., Cormier K.A., Cudkowicz M.E., Brown R.H., Ferrante R.J. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J. Neurochem. 2005, 93:1087-1098.
148. Sugai F., Yamamoto Y., Miyaguchi K., Zhou Z., Sumi H., Hamasaki T., Goto M., Sakoda S. Benefit of valproic acid in suppressing disease progression of ALS model mice. Eur. J. Neurosci. 2004, 20:3179-3183.
149. Dupuis L., Loeffler J.P. Neuromuscular junction destruction during amyotrophic lateral sclerosis: insights from transgenic models. Curr. Opin. Pharmacol. 2009, 9:341-346.
150. Boillee S., Vande Velde C., Cleveland D.W. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 2006, 52:39-59.
151. Del Signore S.J., Amante D.J., Kim J., Stack E.C., Goodrich S., Cormier K., Smith K., Cudkowicz M.E., Ferrante R.J. Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice. Amyotroph. Lateral Scler. 2009, 10:85-94.
152. Cudkowicz M.E., Andres P.L., Macdonald S.A., Bedlack R.S., Choudry R., Brown R.H., Zhang H., Schoenfeld D.A., Shefner J., Matson S., Matson W.R., Ferrante R.J. Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph. Lateral Scler. 2009, 10:99-106.
153. Lefebvre S., Burglen L., Reboullet S., Clermont O., Burlet P., Viollet L., Benichou B., Cruaud C., Millasseau P., Zeviani M., et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995, 80:155-165.
154. Lunke S., El-Osta A. The emerging role of epigenetic modifications and chromatin remodeling in spinal muscular atrophy. J. Neurochem. 2009, 109:1557-1569.
155. Alarcon J.M., Malleret G., Touzani K., Vronskaya S., Ishii S., Kandel E.R., Barco A. Chromatin acetylation, memory, and LTP are impaired in CBP+/- mice: a model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration. Neuron 2004, 42:947-959.
156. Fischer A., Sananbenesi F., Wang X., Dobbin M., Tsai L.H. Recovery of learning and memory is associated with chromatin remodelling. Nature 2007, 447:178-182.
157. Grissom N.M., Lubin F.D. The dynamics of HDAC activity on memory formation. Cellscience 2009, 6:44-48.
158. Dash P.K., Orsi S.A., Moore A.N. Histone deactylase inhibition combined with behavioral therapy enhances learning and memory following traumatic brain injury. Neuroscience 2009, 163:1-8.
159. Guan J.S., Haggarty S.J., Giacometti E., Dannenberg J.H., Joseph N., Gao J., Nieland T.J., Zhou Y., Wang X., Mazitschek R., Bradner J.E., DePinho R.A., Jaenisch R., Tsai L.H. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 2009, 459:55-60.
160. Ricobaraza A., Cuadrado-Tejedor M., Perez-Mediavilla A., Frechilla D., Del Rio J., Garcia-Osta A. Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model. Neuropsychopharmacology 2009, 34:1721-1732.
161. M. Kilgore, C.A. Miller, D.M. Fass, K.M. Hennig, S.J. Haggarty, J.D. Sweatt, G. Rumbaugh, Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 35 (2010) 870-880.
162. Francis Y.I., Fa M., Ashraf H., Zhang H., Staniszewski A., Latchman D.S., Arancio O. Dysregulation of histone acetylation in the APP/PS1 mouse model of Alzheimer's disease. J. Alzheimers Dis. 2009, 18:131-139.
163. Green K.N., Steffan J.S., Martinez-Coria H., Sun X., Schreiber S.S., Thompson L.M., LaFerla F.M. Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J. Neurosci. 2008, 28:11500-11510.
164. McCampbell A., Fischbeck K.H. Polyglutamine and CBP: fatal attraction?. Nat. Med. 2001, 7:528-530.
165. McCampbell A., Taylor J.P., Taye A.A., Robitschek J., Li M., Walcott J., Merry D., Chai Y., Paulson H., Sobue G., Fischbeck K.H. CREB-binding protein sequestration by expanded polyglutamine. Hum. Mol. Genet. 2000, 9:2197-2202.
166. Cong S.Y., Pepers B.A., Evert B.O., Rubinsztein D.C., Roos R.A., van Ommen G.J., Dorsman J.C. Mutant huntingtin represses CBP, but not p300, by binding and protein degradation. Mol. Cell. Neurosci. 2005, 30:560-571.
167. Jiang H., Nucifora F.C., Ross C.A., DeFranco D.B. Cell death triggered by polyglutamine-expanded huntingtin in a neuronal cell line is associated with degradation of CREB-binding protein. Hum. Mol. Genet. 2003, 12:1-12.
168. Jiang H., Poirier M.A., Liang Y., Pei Z., Weiskittel C.E., Smith W.W., DeFranco D.B., Ross C.A. Depletion of CBP is directly linked with cellular toxicity caused by mutant huntingtin. Neurobiol. Dis. 2006, 23:543-551.
169. Jiang Y.M., Yamamoto M., Kobayashi Y., Yoshihara T., Liang Y., Terao S., Takeuchi H., Ishigaki S., Katsuno M., Adachi H., Niwa J., Tanaka F., Doyu M., Yoshida M., Hashizume Y., Sobue G. Gene expression profile of spinal motor neurons in sporadic amyotrophic lateral sclerosis. Ann. Neurol. 2005, 57:236-251.
170. Nikolaev A., McLaughlin T., O'Leary D.D., Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 2009, 457:981-989.
171. Albrecht S., Bourdeau M., Bennett D., Mufson E.J., Bhattacharjee M., LeBlanc A.C. Activation of caspase-6 in aging and mild cognitive impairment. Am. J. Pathol. 2007, 170:1200-1209.
172. Saura C.A., Choi S.Y., Beglopoulos V., Malkani S., Zhang D., Shankaranarayana Rao B.S., Chattarji S., Kelleher R.J., Kandel E.R., Duff K., Kirkwood A., Shen J. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron 2004, 42:23-36.
173. Saha R.N., Ghosh A., Palencia C.A., Fung Y.K., Dudek S.M., Pahan K. TNF-alpha preconditioning protects neurons via neuron-specific up-regulation of CREB-binding protein. J. Immunol. 2009, 183:2068-2078.
174. Kandel E.R. The molecular biology of memory storage: a dialogue between genes and synapses. Science 2001, 294:1030-1038.
175. Hallam T.M., Bourtchouladze R. Rubinstein-Taybi syndrome: molecular findings and therapeutic approaches to improve cognitive dysfunction. Cell. Mol. Life Sci. 2006, 63:1725-1735.
176. Vo N., Goodman R.H. CREB-binding protein and p300 in transcriptional regulation. J. Biol. Chem. 2001, 276:13505-13508.
177. Petrij F., Giles R.H., Dauwerse H.G., Saris J.J., Hennekam R.C., Masuno M., Tommerup N., van Ommen G.J., Goodman R.H., Peters D.J., et al. Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 1995, 376:348-351.
178. Roelfsema J.H., White S.J., Ariyurek Y., Bartholdi D., Niedrist D., Papadia F., Bacino C.A., den Dunnen J.T., van Ommen G.J., Breuning M.H., Hennekam R.C., Peters D.J. Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease. Am. J. Hum. Genet. 2005, 76:572-580.
179. Rubinstein J.H., Taybi H. Broad thumbs and toes and facial abnormalities. A possible mental retardation syndrome. Am. J. Dis. Child. 1963, 105:588-608.
180. Cantani A., Gagliesi D. Rubinstein-Taybi syndrome. Review of 732 cases and analysis of the typical traits. Eur. Rev. Med. Pharmacol. Sci. 1998, 2:81-87.
181. Kalkhoven E., Roelfsema J.H., Teunissen H., den Boer A., Ariyurek Y., Zantema A., Breuning M.H., Hennekam R.C., Peters D.J. Loss of CBP acetyltransferase activity by PHD finger mutations in Rubinstein-Taybi syndrome. Hum. Mol. Genet. 2003, 12:441-450.
182. Van Beekum O., Kalkhoven E. Aberrant forms of histone acetyltransferases in human disease. Subcell. Biochem. 2007, 41:233-262.
183. Korzus E., Rosenfeld M.G., Mayford M. CBP histone acetyltransferase activity is a critical component of memory consolidation. Neuron 2004, 42:961-972.
184. Bourtchouladze R., Lidge R., Catapano R., Stanley J., Gossweiler S., Romashko D., Scott R., Tully T. A mouse model of Rubinstein-Taybi syndrome: defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:10518-10522.
185. Wood M.A., Kaplan M.P., Park A., Blanchard E.J., Oliveira A.M., Lombardi T.L., Abel T. Transgenic mice expressing a truncated form of CREB-binding protein (CBP) exhibit deficits in hippocampal synaptic plasticity and memory storage. Learn. Mem. 2005, 12:111-119.
186. Wood M.A., Attner M.A., Oliveira A.M., Brindle P.K., Abel T. A transcription factor-binding domain of the coactivator CBP is essential for long-term memory and the expression of specific target genes. Learn. Mem. 2006, 13:609-617.
187. Oliveira A.M., Abel T., Brindle P.K., Wood M.A. Differential role for CBP and p300 CREB-binding domain in motor skill learning. Behav. Neurosci. 2006, 120:724-729.
188. Oliveira A.M., Wood M.A., McDonough C.B., Abel T. Transgenic mice expressing an inhibitory truncated form of p300 exhibit long-term memory deficits. Learn. Mem. 2007, 14:564-572.
189. Maurice T., Duclot F., Meunier J., Naert G., Givalois L., Meffre J., Celerier A., Jacquet C., Copois V., Mechti N., Ozato K., Gongora C. Altered memory capacities and response to stress in p300/CBP-associated factor (PCAF) histone acetylase knockout mice. Neuropsychopharmacology 2008, 33:1584-1602.
190. Duclot F., Jacquet C., Gongora C., Maurice T. Alteration of working memory but not in anxiety or stress response in p300/CBP associated factor (PCAF) histone acetylase knockout mice bred on a C57BL/6 background. Neurosci. Lett. 2010, 475:179-183.
191. Okuda S., Roozendaal B., McGaugh J.L. Glucocorticoid effects on object recognition memory require training-associated emotional arousal. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:853-858.
192. Roozendaal B., Okuda S., Van der Zee E.A., McGaugh J.L. Glucocorticoid enhancement of memory requires arousal-induced noradrenergic activation in the basolateral amygdala. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:6741-6746.
193. Chandramohan Y., Droste S.K., Reul J.M. Novelty stress induces phospho-acetylation of histone H3 in rat dentate gyrus granule neurons through coincident signalling via the N-methyl-D-aspartate receptor and the glucocorticoid receptor: relevance for c-fos induction. J. Neurochem. 2007, 101:815-828.
194. Roozendaal B., Hernandez A., Cabrera S.M., Hagewoud R., Malvaez M., Stefanko D.P., Haettig J., Wood M.A. Membrane-associated glucocorticoid activity is necessary for modulation of long-term memory via chromatin modification. J. Neurosci. 2010, 30:5037-5046.
195. Chung Y.H., Kim E.J., Shin C.M., Joo K.M., Kim M.J., Woo H.W., Cha C.I. Age-related changes in CREB binding protein immunoreactivity in the cerebral cortex and hippocampus of rats. Brain Res. 2002, 956:312-318.
196. Fiore P., Gannon R.L. Expression of the transcriptional coactivators CBP and p300 in the hamster suprachiasmatic nucleus: possible molecular components of the mammalian circadian clock. Brain Res. Mol. Brain Res. 2003, 111:1-7.
197. Stromberg H., Svensson S.P., Hermanson O. Distribution of CREB-binding protein immunoreactivity in the adult rat brain. Brain Res. 1999, 818:510-514.